DEF: Immunome, Inc. Sets Date for 2025 Annual Stockholders Meeting

Immunome, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent accounting firm.

Summary

• Immunome, Inc. will hold its 2025 Annual Meeting of Stockholders on June 10, 2025, at 11:30 a.m. Eastern Time, conducted entirely online.
• Stockholders of record as of April 21, 2025, are eligible to vote.
• The meeting will address the election of two Class II directors to serve until the 2028 Annual Meeting, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board recommends voting for the election of the director nominees and for the ratification of the accounting firm appointment.
• The proxy statement and annual report are available online.
• The company's Board consists of seven members: Clay B. Siegall, Carol Schafer, Philip Wagenheim, Isaac Barchas, James Boylan, Jean-Jacques Bienaim, and Sandra M. Swain.
• The Board has determined that Isaac Barchas, Jean-Jacques Bienaim, James Boylan, Carol Schafer, and Sandra M. Swain are independent directors.
• The Nominating Committee recommends Isaac Barchas and Jean-Jacques Bienaim for election as Class II directors.
• The Audit Committee has appointed Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The company's equity compensation plans include the 2020 Plan, ESPP, 2020 MI Plan, and 2024 Inducement Plan.
• As of December 31, 2024, 11,990,781 securities are authorized for issuance under equity compensation plans, with a weighted-average exercise price of $10.02.
• The company completed an underwritten public offering of 22,258,064 shares of its common stock at a purchase price of $7.75 per share in January 2025.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is taking steps to ensure effective corporate governance and incentivize employees, which is viewed positively.

Positives

• The company is providing a virtual meeting option to enable greater stockholder attendance and participation.
• The Board is recommending qualified candidates for election as directors.
• The Audit Committee has appointed a reputable firm, Ernst & Young LLP, as the independent registered public accounting firm.
• The company has a comprehensive set of equity compensation plans to incentivize employees and align their interests with stockholders.
• The company completed an underwritten public offering of 22,258,064 shares of its common stock at a purchase price of $7.75 per share in January 2025.

Risks

• If stockholders fail to ratify the appointment of Ernst & Young LLP, the Audit Committee will reconsider whether to retain that firm.
• The company's future performance is subject to various risks, including those related to research, development, and commercialization of its products.

Future Outlook

The Board is focused on overseeing the company's risk management process and ensuring effective corporate governance.

Management Comments

• Clay B. Siegall, Ph.D., Chairman of the Board, President and Chief Executive Officer, expresses pleasure in inviting stockholders to the Annual Meeting and emphasizes the importance of their vote.

Industry Context

The company operates in the biotechnology industry, which is characterized by high levels of innovation and competition.

Comparison to Industry Standards

• The company's compensation practices are benchmarked against a peer group of companies with comparable stage in key product and corporate development, similar growth and performance potential and market capitalization.
• The 2024 peer group was chosen based on several characteristics including: comparable stage in key product and corporate development, similar growth and performance potential and market capitalization.

Related Party Transactions

• Clay B. Siegall, Ph.D., purchased 150,000 shares for $1.16 million in the January 2025 follow-on offering.
• Immunome Aggregator, L.P., purchased 1,283,399 shares for $9.95 million in the January 2025 follow-on offering.
• Clay B. Siegall, Ph.D., purchased 169,204 shares for $1.00 million in the 2023 PIPE Financing.
• Bruce Turner, M.D., Ph.D., purchased 42,300 shares for $0.25 million in the 2023 PIPE Financing.
• Michael Rapp purchased 253,806 shares for $1.50 million in the 2023 PIPE Financing.

Stakeholder Impact

• Stockholders have the opportunity to vote on important matters related to the company's governance.
• Employees are incentivized through equity compensation plans.
• The company's performance and governance impact its stakeholders, including employees, customers, and suppliers.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will proceed with the Annual Meeting on June 10, 2025.
• The Board and management will continue to execute the company's strategy and oversee its operations.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Stockholders, Ernst & Young, Equity Compensation, Immunome